ZIOPHARM Oncology to Present at the 21st Annual Future Leaders in the Biotech Industry Conference

ZIOPHARM Oncology, Inc. Logo

BOSTON, March 20, 2014 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that Francois Lebel, M.D., Senior Vice President, Clinical Development and Medical Operations, will present at the 21st Annual Future Leaders in the Biotech Industry Conference on Friday, March 28th, 2014 at 3:00 p.m. ET at the Millennium Broadway Hotel in New York City.

To access a live audio webcast of the presentation, please visit the Investor Relations section at www.ziopharm.com. The webcast will be archived for 90 days.

About ZIOPHARM Oncology, Inc.:

ZIOPHARM Oncology is a Boston, Massachusetts-based biotechnology company employing novel gene expression and control technology to deliver DNA for the treatment of cancer. ZIOPHARM's technology platform employs Intrexon Corporation's RheoSwitch Therapeutic System® technology to turn on and off, and precisely modulate, gene expression at the cancer site in order to improve the therapeutic index. This technology is currently being evaluated in Phase 2 clinical studies of the immune system cytokine interleukin-12 for the treatment of breast cancer and advanced melanoma. Multiple new Investigational New Drug applications for new targets using synthetic biology technology are expected through 2015. ZIOPHARM is also developing novel small molecules as potential cancer therapeutics.

CONTACT: Lori Ann Occhiogrosso ZIOPHARM Oncology, Inc. 646-214-0702 locchiogrosso@ziopharm.com

Source:ZIOPHARM Oncology, Inc.